Traws Pharma, Inc. has made headlines with its recent announcement regarding the Phase 2a results for its COVID-19 treatment, Ratutrelvir. The company revealed that this investigational antiviral therapy demonstrated comparable symptom resolution times to PAXLOVID, while also exhibiting fewer treatment-related adverse events. Additionally, Traws completed a bridging study for Tivoxavir Marboxil, further supporting its commitment to developing effective antiviral therapies.
Founded and headquartered in Newtown, Pennsylvania, Traws Pharma operates under the SIC code 2834, which covers Pharmaceutical Preparations. The company is publicly traded on the Nasdaq under the ticker symbol TRAW. Traws Pharma, Inc. is classified as a smaller reporting company and is a non-accelerated filer, which reflects its position in the industry as a clinical-stage biopharmaceutical firm.
The recent SEC filing, dated November 12, 2026, detailed the results of a 92-patient Phase 2a study of Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy aimed at treating COVID-19. The study compared Ratutrelvir to PAXLOVID in patients eligible for the latter treatment. Notably, the median time to symptom resolution was 13.5 days for Ratutrelvir compared to 14.5 days for PAXLOVID. Importantly, no viral rebounds were observed through Day 28, and treatment-related adverse events were significantly lower in the Ratutrelvir group.
"Ratutrelvir showed symptom resolution time comparable to PAXLOVID, with no viral rebound and fewer treatment-related adverse events," the company stated in its press release.
In patients ineligible for PAXLOVID, Ratutrelvir also demonstrated similar efficacy, clearing the virus effectively without any reported treatment-related adverse events. This is particularly significant for older patients who often have limited treatment options due to comorbidities.
Moreover, Traws Pharma has completed a bridging study for Tivoxavir Marboxil, an investigational long-acting prophylactic agent for seasonal and pandemic influenza. The study achieved its objectives, indicating potential for a once-monthly dosing regimen. The results of this study could pave the way for further efficacy studies and regulatory submissions, enhancing Traws' portfolio of antiviral therapies.
The implications of these developments are significant for Traws Pharma and the broader pharmaceutical preparations industry. As the company advances its clinical programs, it may attract attention from investors and healthcare professionals alike. The successful results of Ratutrelvir and the completion of the Tivoxavir Marboxil study may position Traws favorably against competitors in the antiviral space, particularly those focusing on COVID-19 and influenza treatments.
Looking ahead, Traws Pharma plans to discuss a registration path for Ratutrelvir with the FDA, particularly focusing on patients who are ineligible for PAXLOVID. This strategic move could further solidify Traws' position in the market and provide new treatment options for patients with limited alternatives.
As Traws Pharma continues to develop its pipeline, stakeholders will be keen to monitor upcoming filings and announcements that may provide further insights into the company's progress and potential impact on the pharmaceutical industry.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










